Dr Reddy's launches anti-viral drug in US market

Dr Reddy's Laboratories announced today that it has launched anti viral drug Valganciclovir in the US market on Monday after the US Food and Drug Administration (US FDA) granted the approval.

The drug is a therapeutic equivalent generic version of Roche Holdings AG's Valcyte

The Valcyte tablets brand had US sales of approximately $ 440 million for the most recent twelve months ending October, 2014, the company said quoting the IMS data.

Dr Reddy's Valganciclovir tablets in 450 mg is available in bottle counts of 60, according to a press release issued by the company.

Last month Ranbaxy Laboratories had lost the 6-month exclusivity rights on this drug after the US FDA revoked the tentative approvals granted to the company for the launch of the generic version of Valcyte in the US market.

"Thus currently, apart from Dr Reddy's, Endo Pharma has the approval for the drug. The company can add at least $ 60-80 million to the full year sales of the company, if the competition remains low," Sarabjit Kour Nangra of Angel Broking said in a report.